Screener
MapLight Therapeutics, Inc. MPLT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Accounts payable | (111) | (1,050) |
| Accrued expenses | (1,880) | (2,116) |
| Operating lease liabilities | (211) | (184) |
| Net cash used in operating activities | (51,178) | (25,550) |
| Cash flows from investing activities | ||
| Maturities and redemptions of investments | 67,031 | 37,500 |
| Purchases of property and equipment | (24) | — |
| Net cash provided by investing activities | 67,007 | 37,500 |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s operating cash flow?
- MapLight Therapeutics, Inc. (MPLT) reported operating cash flow of -$51.18M in Q1 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about MapLight Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude